Merck, Addex Parkinson’s Venture To Develop Treatments That Target Glutamate Receptor
Firms ink $170 million-plus deal for positive allosteric modulators targeting metabotropic glutamate receptor 4 in Parkinson’s disease and other indications.
Firms ink $170 million-plus deal for positive allosteric modulators targeting metabotropic glutamate receptor 4 in Parkinson’s disease and other indications.